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E.	coli	OP50	 0	 20	 0.0208	 0.0236	 Yes	
E.	coli	E21B		 0	 18	 NA	 NA	 NA	
E.	coli	E21B		 8	 22	 0.0047	 0.0075	 Yes	
E.	coli	E21B		 16	 22	 0.0002	 <0.0001	 Yes	
































































Experiment	2	P-value	compared	to	E21B	 Significant?	 P-value	compared	to	E21B	 Significant?	Log-rank	(Mantel-Cox)	test	 Gehan-Breslow-Wilcoxon	test	
Log-rank	(Mantel-Cox)	test	 Gehan-Breslow-Wilcoxon	test	
E.	coli	OP50	 0	 4	 0.0131	 0.0008	 Yes	 5	 0.0463	 0.1002	 Yes/	No	
E.	coli	E21B	 0	 1	 NA	 NA	 NA	 3	 NA	 NA	 NA	
E.	coli	E21B	 8	 NA	 NA	 NA	 NA	 3	 0.6473	 0.5072	 No	
E.	coli	E21B	 16	 1	 0.0954	 0.0232	 No/	Yes	 3	 0.9106	 0.9233	 No	
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CHAPTER	6	
CONCLUSIONS	
	In	conclusion,	C.	elegans	needs	live	E.	coli	OP50	to	get	enough	nutrients	to	grow	and	survive.	C.	elegans	strain	AU37	is	more	suitable	compared	to	N2	strain	for	the	E.	coli	O157:H7	infection-treatment	assay,	as	AU37	is	more	susceptible	to	bacterial	infection	compared	to	wild-type	N2	strain.		Our	results	indicate	that	C.	elegans	is	an	appropriate	model	to	use	as	an	in-
vivo	study	for	EHEC	infection	and	treatment	as	E.	coli	O157:H7	colonize	the	worm’s	intestine	and	the	treatment	with	ampicillin	concentration	8µg/ml,	16µg/ml,	and	32µg/ml	significantly	increases	the	life-span	of	the	worms	compared	to	the	infected	worms	without	ampicillin	treatment.		In	contrast,	when	ampicillin	treatment	was	used	on	acid-stressed	and	non-acid-stressed	late	exponential	stage	E.	coli	O157:H7	cells,	it	failed	to	increase	the	life-span	of	the	worms	infected	with	acid-stressed	and	non-acid	stressed	E.	coli	O157:H7	cells.	This	may	possibly	be	due	to	the	use	of	late	exponential	stage	E.	coli	O157:H7	cells	compared	to	the	use	of	stationary	phase	E.	coli	O157:H7	cells	in	the	previous	experiment.	In	addition,	ampicillin	treatment	with	concentration	16µg/ml	on	C.	elegans	infected	with	acid-stressed	E.	coli	O157:H7	cells	significantly	reduces	the	life-span	of	the	worms	compared	to	the	ampicillin	treated	(16µg/ml)	non-acid	stressed	E.	coli	O157:H7	cells,	even	though	ampicillin	reduces	the	intestinal	bacterial	colonization	to	approximately	1.8	log	compared	to	approximately	1	log	for	non-acid	
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stressed	E.	coli	O157:H7.	Hence,	further	studies	need	to	perform	to	understand	such	effect	on	the	life-span	of	the	worms.		 	
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APPENDIX	
EXPANDED	LAB	PROCEDURES	
E.	COLI	O157:H7	INFECTION-TREATMENT	IN	C.	ELEGANS	PROCEDURE	
	
1. Preparation	of	nematode	growth	media	(NGM)	plate	and	concentrated	
E.	coli	OP50	
• Prepare	NGM	plate	and	concentrated	E.	coli	OP50	a	week	before	the	start	of	the	experiment.		
A. NGM	plate	seeded	with	OP50	preparation	
o Prepare	NGM	plate	using	NGM	growth	media	and	follow	the	manufacture	instructions.		
o Grow	E.	coli	OP50	in	a	Luria-Bertani	broth	for	12-14	hours	at	37°C	and	pipet	1ml	onto	each	of	the	2	days	old	NGM	plate.	Let	the	plate	sit	at	the	room	temperature	for	another	two	days.	This	is	referred	to	as	OP50	seeded	NGM	plates.	Store	the	plates	at	4°C	till	ready	to	use.	
B. Concentrated	E.	coli	OP50	
o Grow	E.	coli	OP50	in	a	Luria-Bertani	broth	for	12-14	hours	at	37°C	and	centrifuge	using	a	50ml	centrifuge	tube,	collect	the	pellet	and	discard	the	supernatant	
o Weigh	the	pellet	and	prepare	100	mg/ml	OP50	concentration	using	sterile	water.	This	is	referred	to	as	concentrated	OP50	for	C.	elegans	food	in	96	transwell	plate.		
2. C.	elegans	stock	culture	preparation	
• Chunk	a	piece	of	agar	containing	many	AU37	worms	received	from	CGC	or	from	your	old	NGM	plate	containing	AU37	worms	and	place	it	onto	your	freshly	prepared	NGM	agar	seeded	with	OP50.	Incubate	the	plate	at	15°C.	Plate	can	be	stored	at	15°C	for	up	to	4	months	and	can	be	used	when	needed.			
3. Infection-Treatment	life-span	assay	using	C.	elegans	strain	AU37	
	
Day	1:	Chunk	a	piece	of	NGM	agar	
• Chunk	a	piece	of	agar	containing	many	AU37	worms	and	transfer	it	onto	three	new	NGM	plates	seeded	with	OP50.	Incubate	the	plates	at	15°C	for	approximately	4	days	for	the	worms	to	lay	eggs.		
Day	5:	Collect	the	eggs	(synchronization	of	worms)		
• Wash	each	of	the	NGM	plates	having	many	eggs	with	approximately	3	ml	sterile	water	for	couple	of	time.	Dispense	the	washed	liquid	containing	worms	into	15ml	centrifuge	tube.	
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• Centrifuge	at	2000g	for	2mins.	Discard	the	supernatant.		
• Prepare	10ml	bleach	solution	(1ml	10M	NaOH,	1.8ml	household	bleach,	and	7.2ml	sterile	water)	into	a	15ml	centrifuge	tube	(You	can	prepare	5ml	or	10ml	bleach	depends	on	the	density	of	worms	you	have).	
• Add	the	bleach	solution	to	the	washed	worms	tube,	and	vortex	at	high	speed	for	2mins.	Centrifuge	at	2000g	for	1min	and	discard	the	supernatant.	Add	approximately	10ml	M9	buffer	to	neutralize	the	bleach	effect	and	vortex	little	(All	this	process	in	this	step	should	be	really	fast,	should	not	exceed	>3.5	mins,	or	the	eggs	won’t	hatch	out	the	next	day),	and	then	centrifuge	at	2000g	for	2mins,	and	discard	the	supernatant.	At	this	stage	you	should	have	only	eggs	in	your	tube	(may	contains	few	dead	worms).	
• Add	10ml	M9	buffer	one	more	time	and	centrifuge	at	2000g	for	another	2mins,	discard	the	supernatant,	and	add	1ml	of	M9	buffer.	
• Incubate	the	centrifuge	tube	containing	eggs	horizontally	at	25°C	for	24	hours	for	the	eggs	to	hatch	out.	After	24	hours	the	worms	should	be	in	L1	stage.		
Day	6:	Transfer	of	L1	stage	worms	and	E21B	streak	plate	A. Transfer	the	L1	stage	worms	using	a	pipet	onto	NGM	plate	seeded	with	OP50	and	incubate	the	plate	at	25°C	for	45-50	hours.	Worms	should	be	at	L4-young	adult	stage	after	45-50	hours.	B. Streak	a	new	Tryptic	Soy	Agar	(TSA)	plate	from	a	frozen	E21B	stock	and	incubate	at	37°C	for	18-20	hours.	Follow	the	same	procedure	with	OP50.		
Day	7:	E21B	and	OP50	culture	preparation	
• Transfer	3	colonies	from	streaked	E21B	from	Day	6	into	two	10ml	Luria-Bertani	broth.	Incubate	the	tubes	at	37°C	for	18-20	hours	on	a	125rpm	shaker.	Follow	the	same	procedure	with	OP50.		
Day	8:	Infecting	worms	with	E21B		
A. Preparation	of	E21B	and	OP50	culture		
• Take	out	E21B	and	OP50	culture	tubes	from	Day	7,	dilute	the	culture	10x,	and	read	the	absorbance	at	wavelength	625nm	using	spectrophotometer.	Absorbance	of	0.08	–	0.1	at	wavelength	625nm	is	consider	having	approximately	108	CFU/ml	bacteria.	
• Centrifuge	the	original	9	ml	E21B	and	OP50	culture	containing	approximately	109	CFU/ml	bacteria	at	2500g	for	10	minutes	and	discard	the	supernatant.		
• Add	0.9	ml	M9	buffer	to	each	tube	to	make	the	final	bacterial	concentration	of	1010	CFU/ml.		
B. Preparation	of	worms		
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• Pipet	approximately	2-3ml	M9	buffer	into	each	of	the	Day	6	plates	containing	synchronized	L4-young	adult	stage	AU37	worms	and	collect	it	into	a	15ml	centrifuge	tube.	Centrifuge	the	worms	at	2000g	for	1min	with	M9	buffer	three	times	to	remove	any	OP50	residue.	Discard	the	supernatant	using	pipet.		
• Add	1ml	of	M9	buffer	and	transfer	the	mixture	into	2ml	micro	centrifuge	tube.	
• Pipet	five	10	µl	drops	on	a	sterile	petri	dish	and	count	the	number	of	worms.	Average	the	worms	per	10	µl	and	record	the	number.		
C. Infection	in	24	well	plate	
• Add	approximately	100	worms	into	24	well	plate	and	make	the	final	volume	to	900	µl	using	M9	buffer.	
• Add	100	µl	E21B	to	make	the	final	E21B	concentration	of	109	CFU/ml.	Run	control	on	side	by	adding	100	µl	OP50	to	make	the	final	OP50	concentration	of	109	CFU/ml.	
• Incubate	the	plate	at	25°C	for	24	hours.		
Day	9:	Treatment	with	ampicillin		
A. Preparation	of	bacterial	food	with	varied	ampicillin	concentration	
• Add	concentrated	OP50	to	the	final	concentration	of	3mg/ml	and	ampicillin	to	the	final	desired	concentration	using	M9	buffer	in	a	sterile	tube.	Mix	the	mixture	well	for	1min	using	vortex	at	high	speed.	
• Add	250	µl	of	the	food	mixture	to	the	bottom	of	96	transwell	plate.	
	
B. Preparing	and	adding	worms	to	use	in	96	transwell	plate	
• Transfer	infected	worms	(E21B)	from	Day	8	into	15ml	centrifuge	tube.	Follow	same	procedure	for	control	(OP50)	worms.	
• Centrifuge	the	worms	at	2000g	for	1	minute	and	discard	the	supernatant.	Add	M9	buffer	and	repeat	the	procedure	five	times	to	remove	most	residue	of	E21B	and	OP50.		
• Pipet	five	10µl	drops	of	each	of	the	infected	and	control	worms	into	a	sterile	petri	dish	to	determine	the	number	of	worms	per	10µl.	Average	and	record	the	number.	
• Transfer	approximately	10	infected	worms	into	a	micro	centrifuge	tube	to	determine	the	bacterial	colonization	in	worms’	intestine.	
• Transfer	approximately	10	worms	into	each	of	the	insert	well	in	transwell	plate	containing	food	in	the	bottom	wells.		
• Incubate	the	plate	at	25°C	and	record	the	number	of	viable	worms	every	day	to	every	other	day.	
	
C. Bacterial	colonization	in	the	worms	
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• Add	1mM	sodium	azide	to	the	final	volume	of	250µl	into	approximately	10	infected	worms	tube.	
• Centrifuge	the	worms	at	2000g	for	1min	and	discard	the	supernatant	using	pipet.	Add	1mM	sodium	azide	to	the	final	volume	of	250µl	and	repeat	the	step	3	times.		
• Add	50µl	of	supernatant	to	the	Sorbitol	MacConkey	Agar	to	determine	the	external	bacterial	count.		
• Add	approximately	400mg	of	1mm	silicon	carbide	particles	into	the	tube	containing	10	infected	worms	and	vortex	at	high	speed	for	1min	to	disrupt	the	worms.	
• Perform	serial	dilution	and	plate	onto	Sorbitol	MacConkey	Agar	to	determine	total	bacterial	count	(Internal	+	External)	per	10	worms.	
• Incubate	the	plates	at	37°C	for	18-20	hours.		 	
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